News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News EuroPCR 2023 ADALA: Low-Dose Apixaban Tops DAPT After LAA Closure Todd Neale May 18, 2023
News Conference News TCT 2021 PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term Todd Neale November 05, 2021
News Conference News ESC 2021 OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT Shelley Wood September 02, 2021
News Conference News TCT 2019 AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups Todd Neale September 26, 2019
News Conference News ESC 2019 Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints Todd Neale September 11, 2019
News Conference News ESC 2018 Atrial Fibrillation, Oral Anticoagulation Linked With Mortality After TAVR: FRANCE-TAVI Michael O'Riordan August 25, 2018
News Conference News SCAI 2018 Doctors, Risk Tools Often at Odds When Assessing Risks in Patients With A-fib Undergoing PCI Todd Neale April 27, 2018
News Conference News EuroPCR 2017 EWOLUTION Analysis Backs LAA Closure in High-Risk Patients Taking DAPT, Not Warfarin, After Procedure Michael O'Riordan May 24, 2017
News Conference News AHA 2016 Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI Todd Neale November 14, 2016